Drug
Vancomycin (POC)
Vancomycin (POC) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
67%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Withdrawn1
Completed1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (66.7%)
Phase 41 (33.3%)
Trials by Status
withdrawn133%
completed133%
not_yet_recruiting133%
Recent Activity
0 active trials
Showing 3 of 3
withdrawnphase_2
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
NCT07221708
not_yet_recruitingphase_4
Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease
NCT06794944
completedphase_2
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
NCT01232595
Clinical Trials (3)
Showing 3 of 3 trials
NCT07221708Phase 2
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
NCT06794944Phase 4
Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease
NCT01232595Phase 2
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3